Program
Gabapentin
Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 201 open or running | phase 4since Sep 28, 2007 | Sep 8, 2005 | Jan 31, 2027phase 4 · NCT07813026 |
| Depomed | 80 open or running | phase 4since Jun 5, 2017 | Jun 8, 2006 | none ahead |
| Teva Pharmaceutical Industries | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Sun Pharmaceutical Industries | 40 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 1since Sep 29, 2011 | Sep 29, 2011 | none ahead |
| Pharmaceutical Research Management srl | 20 open or running | phase 3since Mar 18, 2016 | Mar 18, 2016 | none ahead |
| Nang Kuang Pharmaceutical | 10 open or running | phase 4since Feb 24, 2014 | Feb 24, 2014 | none ahead |
| Pfizer | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
Also a collaborator on its studies: chiltern-international-inc and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since Sep 8, 2005.
- Sep 30, 2009Phase 1 study in HealthyViatris · NCT00987779 · 26 enrolled · Singapore
- Mar 2, 2010Phase 3 study in Hot FlashesDepomed · NCT01080300 · 600 enrolled · United States
- May 5, 2010Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT01119222 · 19 enrolled · Belgium
- Sep 29, 2011GlaxoSmithKline's first study: phase 1 study in NeuralgiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT01485185 · 48 enrolled · United Kingdom
- Nov 28, 2012Phase 1 study in EpilepsyGlaxoSmithKline · NCT01738893 · 26 enrolled
- Jun 25, 2013Phase 3 study in Sleep Initiation and Maintenance DisordersViatris · NCT01888497 · 59 enrolled · United States
- Feb 24, 2014Nang Kuang Pharmaceutical's first study: phase 4 study in PainNew to Nang Kuang PharmaceuticalNang Kuang Pharmaceutical · NCT02074267 · 40 enrolled · Taiwan
- Mar 18, 2016Pharmaceutical Research Management srl's first study: phase 3 study in Chronic PainNew to Pharmaceutical Research Management srlPharmaceutical Research Management srl · NCT02722603 · 2 enrolled · Germany, Netherlands
- Jun 5, 2017Phase 4 study in HealthyDepomed · NCT03179345 · 32 enrolled
- Aug 30, 2017Phase 2 study in Chronic PainPharmaceutical Research Management srl · NCT03275012
- Sep 24, 2020Phase 4 study in Abuse PotentialViatris · NCT04570436 · 52 enrolled · United States
- Mar 8, 2022Phase 4 study in Abuse PotentialViatris · NCT05319756 · 54 enrolled · United States
- Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersViatris · NCT07777965 · 44 enrolled · United States
- Sep 4, 2026Phase 4 study in HealthyViatris · NCT07813026 · 60 planned · United States
Ahead
- Jan 31, 2027Primary completion: phase 4 study in HealthyViatris · NCT07813026
TargetBeta
“Voltage-gated calcium channel modulator”ChEMBL 37, by rule
Other programs on the same 26 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07813026Healthy · United States | 4 | Recruiting | Viatris | Jan 31, 2027 | 60 |
| NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States | 4 | Completed | Viatris | Aug 31, 2026 | 44 |
| NCT05319756Abuse Potential · United States | 4 | Completed | Viatris | Dec 31, 2021 | 54 |
| NCT04570436Abuse Potential · United States | 4 | Completed | Viatris | Nov 10, 2022 | 52 |
| NCT03275012Chronic Pain | 2 | Withdrawn | Pharmaceutical Research Management srl | Oct 21, 2019 | 0 |
| NCT03179345Healthy | 4 | Completed | Depomed | Nov 20, 2015 | 32 |
| NCT02722603Chronic Pain · Germany, Netherlands | 3 | Terminated | Pharmaceutical Research Management srl | May 31, 2019 | 2 |
| NCT02074267Pain · Taiwan | 4 | Completed | Nang Kuang Pharmaceutical | Jun 2011 | 40 |
| NCT01888497Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | Dec 14, 2013 | 59 |
| NCT01738893Epilepsy | 1 | Completed | GlaxoSmithKline | Jan 22, 2011 | 26 |
| NCT01485185Neuralgia · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 3, 2012 | 48 |
| NCT01119222Healthy · Belgium | 1 | Completed | Pfizer | Oct 2008 | 19 |
| NCT01080300Hot Flashes · United States | 3 | Completed | Depomed | Sep 2011 | 600 |
| NCT00987779Healthy · Singapore | 1 | Completed | Viatris | Oct 2009 | 26 |
| NCT00865631Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 1999 | 18 |
| NCT00865423Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Feb 2001 | 28 |
| NCT00865059Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Feb 2001 | 24 |
| NCT00864760Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 1999 | 30 |
| NCT00864305Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 1998 | 18 |
| NCT00864058Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 1998 | 30 |
| NCT00785772Renal Insufficiency · Japan | 4 | Terminated | Viatris | Apr 2010 | 1 |
| NCT00778765Healthy · Canada | – | Completed | Sun Pharmaceutical Industries | Oct 2002 | 24 |
| NCT00778401Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2002 | 28 |
| NCT00778271Healthy · Canada | – | Completed | Sun Pharmaceutical Industries | Oct 2002 | 26 |
| NCT00778232Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Nov 2002 | 22 |
| NCT00777023Hot Flashes · United States | 3 | Completed | Depomed | Jul 2009 | 565 |
| NCT00755417Hot Flashes · United States | 3 | Completed | Depomed | Aug 2009 | 541 |
| NCT00712439Pain | 2 | Completed | Depomed | Nov 2006 | 147 |
| NCT00674752Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 377 | |
| NCT00667108Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 784 | |
| NCT00666939Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 773 | |
| NCT00666796Sleep Initiation and Maintenance Disorders · United States | 4 | Completed | Viatris | 20 | |
| NCT00666770Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 309 | |
| NCT00666575Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 2,105 | |
| NCT00659100Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 1,254 | |
| NCT00644748Diabetic Neuropathies · Brazil | 4 | Completed | Viatris | 95 | |
| NCT00636636Neuralgia, Postherpetic · United States, Argentina, Russian Federation | 3 | Completed | Depomed | Aug 2009 | 452 |
| NCT00620555Epilepsies, Partial · Japan | 3 | Completed | Viatris | Dec 2010 | 65 |
| NCT00603473Epilepsies, Partial · Japan | 3 | Completed | Viatris | Dec 2009 | 92 |
| NCT00584779Renal Insufficiency · Japan | 4 | Terminated | Viatris | Dec 2007 | 8 |
| NCT00537940Epilepsy · Costa Rica, El Salvador, Guatemala and more | 4 | Completed | Viatris | Jul 2013 | 482 |
| NCT00511953Hot Flashes · United States | 2 | Completed | Depomed | Dec 2007 | 108 |
| NCT00335933Neuralgia, Postherpetic · United States | 3 | Completed | Depomed | 378 | |
| NCT00163046Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Viatris | 256 |
How it is read
Names in the registry
- “Gabapentin”, 27 entries
- “gabapentin”, 5 entries
- “gabapentin 600 mg”, 3 entries
- “Gabapentin Extended Release tablets”, 3 entries
- “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Hot Flashes, 4 studies
- Diabetic Neuropathies, 3 studies
- Epilepsies, Partial, 3 studies
- Neuralgia, Postherpetic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.